AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35506388
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium channel blockers
Trial: 35665728
Drug: Nintedanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib plus pirfenidone (combination group)
Trial: 33177138
Drug: No discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No discontinuation
Trial: 33248570
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg virginiamycin (antibiotic)
Trial: 35088616
Drug: Questionnaires administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questionnaires administered via paper booklets, interactive voice response system, or tablet web survey
Trial: 32896653
Drug: Viaskin-PT 25
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin-PT 25 μg
Trial: 32896653
Drug: Viaskin-PT 50
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin-PT 50 μg
Trial: 37330602
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine
Trial: 34269848
Drug: MB02 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB02 (3 mg/kg IV dose)
Trial: 34269848
Drug: Reference bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference bevacizumab (3 mg/kg IV dose)
Trial: 32771276
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg IV every 3 weeks and PLD 40 mg/m2 IV every 4 weeks
Trial: 32771276
Drug: Pembrolizumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab and PLD combination therapy
Trial: 33729323
Drug: Chahuang ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chahuang ointment
Trial: 33729323
Drug: Mucopolysaccharide Polysulfate
RxNorm normalized name: Mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucopolysaccharide Polysulfate cream
Trial: 33161472
Drug: Sunscreen formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen formulations with nanostructured lipid carriers (NLCs) containing quercetin
Trial: 33161472
Drug: Sunscreen formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen formulations without antioxidants
Trial: 32452208
Drug: HGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGH treatment
Trial: 33000891
Drug: Long-term injectable
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term injectable opioid agonist treatment with diacetylmorphine (DAM)
Trial: 36526521
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg daily)
Trial: 33764619
Drug: CX-8998 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-8998 (10 mg twice daily)
Trial: 35365958
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of low-dose methotrexate (12.5 mg once per week)
Trial: 35365958
Drug: Both daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both daily and weekly administration of low-dose methotrexate
Trial: 35365958
Drug: Daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and weekly administration of low-dose methotrexate
Trial: 616038469
Drug: Topical brinzolamide
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab
Trial: 36164983
Drug: Cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol (CF) 1350 mg
Trial: 34520130
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators (6 weeks)
Trial: 34520130
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators + inhaled corticosteroids (ICS) (12 weeks)
Trial: 34520130
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators + ICS
Trial: 34570004
Drug: Web-based training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based training, four-session telephone follow-up, and one text message weekly
Trial: 32109257
Drug: Adaptable implementation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptable implementation package targeting co-prescription of aspirin and clopidogrel without gastro-protection
Trial: 33177324
Drug: Hydrocodone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone administration by parents with high anxiety
Trial: 33177324
Drug: Hydrocodone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone administration by parents with high stress
Trial: 33177324
Drug: Acetaminophen administration
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administration influenced by parental coping styles
Trial: 39311597
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections
Trial: 32505171
Drug: No glucose
RxNorm normalized name: No glucose hemofiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucose infusion (0G group)
Trial: 32067100
Drug: Less invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less invasive surfactant administration (LISA)
Trial: 32115970
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment of sepsis)
Trial: 35079895
Drug: IMO/sucromalt combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO/sucromalt combination
Trial: 34072630
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of elemental iron as ferrous sulfate
Trial: 39709368
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy (ACT)
Trial: 35929569
Drug: Diaphragm pacemaker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm pacemaker and pulmonary rehabilitation therapies along with basic ICU nursing and conventional rehabilitation treatment
Trial: 35929569
Drug: Basic ICU
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic ICU nursing and conventional rehabilitation treatment
Trial: 35929569
Drug: Diaphragm pacemaker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm pacemaker and pulmonary rehabilitation therapies
Trial: 33527332
Drug: Replacement with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement with H2 blockers (Group B)
Trial: 33527332
Drug: H2 blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 blockers (Group D)
Trial: 34511458
Drug: Integrated use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated use of climatic‐, balneo‐ and focused magnetic therapy with anti‐tuberculosis chemotherapy
Trial: 34511458
Drug: Drinking mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking mineral water 'Teberda' in addition to anti‐tuberculosis chemotherapy
Trial: 34511458
Drug: Focused magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused magnetic therapy in addition to drinking mineral water 'Teberda' and anti‐tuberculosis chemotherapy
Trial: 34511458
Drug: Climatic‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climatic‐ and anti‐tuberculosis chemotherapy (comparison group)
Trial: 33737410
Drug: Co-amoxiclav 400/57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 400/57 twice daily for 5 days
Trial: 33326711
Drug: HP-3070 7.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-3070 7.6 mg/24 h
Trial: 33326711
Drug: HP-3070 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-3070 3.8 mg/24 h
Trial: 39290680
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) alone
Trial: 32562206
Drug: Dabigatran dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor)
Trial: 32562206
Drug: Warfarin triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin triple therapy (with clopidogrel or ticagrelor, and aspirin for 1-3 months)
Trial: 35901367
Drug: Engagement-focused parent-teen
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engagement-focused parent-teen treatment (STAND)
Trial: 32864754
Drug: Tetramethylpyrazine nitrone
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine nitrone (TBN) 50-1800 mg IV infusion over 30 min (SAD study)
Trial: 32864754
Drug: Tetramethylpyrazine nitrone
RxNorm normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetramethylpyrazine nitrone (TBN) 700 or 1400 mg twice daily for 6.5 days (MAD study)
Trial: 33380585
Drug: Pectoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoral nerve block with 10 mL of 2% lignocaine as an initial bolus followed by 10 mL every 8 hours up to 24 hours (Group I)
Trial: 34059372
Drug: Vaccines For
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccines For Babies (VFB) intervention
Trial: 33323886
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention administered by a psychiatrist before surgery and ongoing thereafter
Trial: 33302648
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 4000, 10 g, twice daily
Trial: 34986170
Drug: Zvandiri peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zvandiri peer counselling with problem-solving therapy (PST)
Trial: 37584344
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine
Trial: 35121700
Drug: Oxcarbazepine (900-2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (900-2400 mg/day)
Trial: 35121700
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (about 20 mg/kg/day)
Trial: 32130025
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion for 7 hours at night
Trial: 32130025
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) infusion for 7 hours at night
Trial: 38045523
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion
Trial: 36282078
Drug: L-arginine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (0.1 mg.kg‐1 daily)
Trial: 32335343
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg/day)
Trial: 35300246
Drug: Trimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodal therapy followed by gemcitabine maintenance (Arm A)
Trial: 35776901
Drug: Conventional schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional schedule radiation therapy
Trial: 34217550
Drug: HBM-based rational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM-based rational use of drugs training
Trial: 39108325
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: 36153030
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation (PR) programme comprising 16 twice‐weekly group sessions tailored to the Georgian setting.
Trial: 34028828
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment and Hall Technique (ART/HT)
Trial: 33278014
Drug: Daily Report
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Report
Trial: 36173064
Drug: Repeated-dose intravenous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-dose intravenous ketamine
Trial: 33004704
Drug: Dexmedetomidine-ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-ketamine (1 μg/kg dexmedetomidine and 0.5 mg/kg ketamine)
Trial: 33004704
Drug: Fentanyl-ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl-ketamine (2 μg/kg fentanyl and 0.5 mg/kg ketamine)
Trial: 34233722
Drug: Cybernic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cybernic treatment with HAL (40-min walking program performed nine times)
Trial: 34233722
Drug: Hoist only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoist only treatment
Trial: 34233722
Drug: Cybernic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cybernic treatment with HAL
Trial: 36332179
Drug: Margetuximab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margetuximab (15 mg/kg intravenously once every 3 weeks)
Trial: 36332179
Drug: Trastuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg)
Trial: 36749915
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment
Trial: 32227309
Drug: S. salivarius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. salivarius K12 tablet
Trial: 36428171
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy plus abiraterone with or without apalutamide
Trial: 36428171
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (RP without neoadjuvant therapy)
Trial: 36087863
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2
Trial: 36214032
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (100 kVp, 350 mgI/ml CM)
Trial: 36214032
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (80 kVp, 320 mgI/ml CM)
Trial: 32725293
Drug: 2 portions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 portions of fish per week (140 g per portion)
Trial: 32725293
Drug: 1 portion
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 portion of fish per week (140 g per portion)
Trial: 34110395
Drug: General oncologist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General oncologist treatment style
Trial: 33040720
Drug: Trastuzumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab treatment
Trial: 32966144
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (PCV)
Trial: 36445398
Drug: Pregnenolone 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone 300 mg
Trial: 36445398
Drug: Pregnenolone 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone 500 mg
Trial: 36445398
Drug: Pregnenolone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (both doses)
Trial: 33296549
Drug: Cyclosporine (CSA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CSA) (2.5‐5 mg/kg/d)
Trial: 33296549
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) (7.5‐15 mg/week)
Trial: 33296549
Drug: Acitretin (ACT)
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin (ACT) (25‐50 mg/d)
Trial: 32402684
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate (FF) 200 mg three times a day (total daily dose: 195 mg elemental iron)
Trial: 32402684
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous gluconate (FG) 695 mg twice a day (total daily dose: 160 mg elemental iron)
Trial: 32402684
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) 1000 mg elemental iron (single dose)
Trial: 33789963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during the third trimester)
Trial: 33789963
Drug: TDF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF therapy during the third trimester of pregnancy
Trial: 35247098
Drug: Wheat aleurone
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat aleurone (27 g/day)
Trial: 35247098
Drug: Cellulose (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose (placebo treatment)
Trial: 37610332
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment
Trial: 32275670
Drug: Unilateral radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unilateral radiation therapy
Trial: 32275670
Drug: Bilateral radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral radiation therapy
Trial: 34308517
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg twice daily
Trial: 32840598
Drug: Genotype-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided therapy (ticagrelor for LOF carriers)
Trial: 32840598
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (clopidogrel)
Trial: 32840598
Drug: Genotype-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided therapy (all randomized patients)
Trial: 32840598
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (all randomized patients)
Trial: 32840598
Drug: Genotype-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided therapy (major or minor bleeding)
Trial: 32840598
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (major or minor bleeding)
Trial: 34192907
Drug: Smartphone-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based care platform (treatment group)
Trial: 33892154
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy
Trial: 35654467
Drug: Hypotension Prediction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotension Prediction Index (HPI) based treatment protocol
Trial: 34289889
Drug: Hemostatic agent
RxNorm normalized name: Hemostatic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic agent
Trial: 38519416
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Control)
Trial: 33095509
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of albuterol
Trial: 33095509
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of albuterol
Trial: 35364589
Drug: Clazosentan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (10 mg/hr)
Trial: 35434578
Drug: 25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg RBD vaccine (long schedule)
Trial: 35434578
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg RBD vaccine (long schedule)